Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 319

The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.

Gabapentin for Neuropathic Cancer Pain: A Randomized Controlled Trial From the Gabapentin Cancer Pain Study Group

Caraceni, Augusto, Zecca, Ernesto, Bonezzi, Cesare, Arcuri, Edoardo, Tur, Ricardo Yaya, Maltoni, Marco, Visentin, Marco, Gorni, Giovanna, Martini, Cinzia, Tirelli, Walter, Barbieri, Massimo, De Conno, Franco·2004·Journal of Clinical Oncology

Abstract

Purpose: To determine the analgesic effect of the addition of gabapentin to opioids in the management of neuropathic cancer pain. Patients and Methods: One hundred twenty-one consecutive patients with neuropathic pain due to cancer, partially controlled with systemic opioids, participated in a multicenter, randomized, double-blind, placebo-controlled, parallel-design, 10-day trial from August 1999 to May 2002. Gabapentin was titrated from 600 mg/d to 1,800 mg/d in addition to stable opioid dose. Extra opioid doses were available as needed. Zero to 10 numerical scale was used to rate average daily pain. The average pain score over the whole follow-up period was used as main outcome measure. Secondary outcome measures were: intensity of burning pain, shooting/lancinating pain, dysesthesias (also scored on 0 to 10 numerical scale), number of daily episodes of lancinating pain, presence of allodynia, and daily extra doses of opiod analgesics. Results: Overall, 79 patients received gabapentin and 58 (73%) completed the study; 41 patients received placebo and 31 (76%) completed the study. Analysis of covariance (ANCOVA) on the intent-to-treat population showed a significant difference of average pain intensity between gabapentin (pain score, 4.6) and placebo group (pain score, 5.4; P = .0250). Among secondary outcome measures, dysesthesia score showed a statistically significant difference (P = .0077; ANCOVA on modified intent-to-treat population = 115 patients with at least 3 days of pain assessments). Reasons for withdrawing patients from the trial were adverse events in six patients (7.6%) receiving gabapentin and in three patients receiving placebo (7.3%). Conclusion: Gabapentin is effective in improving analgesia in patients with neuropathic cancer pain already treated with opioids.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2004.08.141

Cites

34 of 34 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 34 references

Cited by

See all 319

Metadata

Authors
Caraceni, A., Zecca, E., Bonezzi, C., Arcuri, E., Tur, R. Y., Maltoni, M., Visentin, M., Gorni, G., Martini, C., Tirelli, W., Barbieri, M., & De Conno, F.
Venue
Journal of Clinical Oncology
Published
2004-07-15
Volume
22
Issue
14
Pages
2909-2917
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2141918005
Cited by
319
References
34
FWCI
18.92
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gabapentin for Neuropathic Cancer Pain: A Randomized Controlled Trial From the Gabapentin Cancer Pain Study Group. https://app.cochat.ai/papers/10.1200/jco.2004.08.141
The paper
Caraceni, A., Zecca, E., Bonezzi, C., Arcuri, E., Tur, R. Y., Maltoni, M., Visentin, M., Gorni, G., Martini, C., Tirelli, W., Barbieri, M., & De Conno, F. (2004). Gabapentin for Neuropathic Cancer Pain: A Randomized Controlled Trial From the Gabapentin Cancer Pain Study Group. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2004.08.141

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.